Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.

@article{Wolzt2011EffectOE,
  title={Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.},
  author={Michael Wolzt and Meyer Michel Samama and Stylianos Kapiotis and Koichiro Ogata and Jeanne Mendell and Satoshi Kunitada},
  journal={Thrombosis and haemostasis},
  year={2011},
  volume={105 6},
  pages={1080-90}
}
Edoxaban, an oral direct factor Xa (FXa) inhibitor, is in phase III clinical development for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. The shed blood model allows for study of activated coagulation at a site of standardised tissue injury due to local release of tissue factor. The objective of this study was to evaluate the effect of three doses of edoxaban on markers of coagulation in shed and venous blood versus placebo and a standard prophylactic dose… CONTINUE READING
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…